What Is the Difference Between Semaglutide and Tirzepatide: Mechanism, Efficacy, and Which One Works Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide activates only GLP-1 receptors, while tirzepatide activates both GLP-1 and GIP receptors, creating different metabolic effects and weight loss patterns
• Tirzepatide produces 15-22% average weight loss at maximum dose compared to 12-15% for semaglutide, but individual response varies more than the averages suggest
• Nausea rates are similar (30-35% during titration), but tirzepatide shows higher rates of diarrhea while semaglutide shows slightly higher constipation
• The choice between them depends on insurance coverage, individual side effect tolerance, and whether you're treating obesity alone or obesity plus type 2 diabetes

Direct answer (40-60 words)

Semaglutide is a GLP-1 receptor agonist that mimics one gut hormone. Tirzepatide is a dual GLP-1/GIP receptor agonist that mimics two. Tirzepatide produces greater average weight loss (20% vs 15% at maximum doses) but costs more and causes more GI side effects in some patients. Both work through similar appetite suppression mechanisms.

Table of contents

1. The core mechanism difference: one receptor vs two
2. Head-to-head weight loss data: what the trials actually show
3. Side effect profiles: where they diverge and why
4. The dosing and titration comparison
5. What most articles get wrong about "dual agonist superiority"
6. The FormBlends clinical pattern: who responds better to which medication
7. Cost and access differences in 2026
8. The decision framework: which medication fits your situation
9. When switching from one to the other makes sense
10. The combination question: can you use both together?
11. FAQ
12. Sources

The core mechanism difference: one receptor vs two

Both medications belong to the incretin mimetic class. They mimic gut hormones released after eating that tell your brain you're full and tell your pancreas to release insulin. The difference is how many hormones they mimic.

Semaglutide activates GLP-1 (glucagon-like peptide-1) receptors only. GLP-1 is released by L-cells in your small intestine after meals. When GLP-1 binds to receptors in the brain, pancreas, and stomach, three things happen:

1. Appetite suppression. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signals and increase satiety.
2. Slowed gastric emptying. Food stays in your stomach longer, extending the feeling of fullness.
3. Glucose-dependent insulin release. Your pancreas releases insulin only when blood sugar is elevated, reducing hypoglycemia risk.

Tirzepatide activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is released by K-cells in the upper small intestine. Adding GIP activation creates additional effects:

1. Enhanced insulin secretion. GIP amplifies the insulin response beyond what GLP-1 alone produces.
2. Reduced glucagon. GIP suppresses glucagon (a hormone that raises blood sugar) more effectively than GLP-1 alone.
3. Increased energy expenditure. GIP receptors in adipose tissue may increase fat breakdown and thermogenesis, though this mechanism is still being studied (Frias et al., Lancet 2021).
4. Different satiety signaling. GIP works through different brain pathways than GLP-1, potentially creating a stronger combined appetite suppression effect.

The simplified version: semaglutide pulls one lever (GLP-1). Tirzepatide pulls two levers (GLP-1 plus GIP). The dual action explains why tirzepatide produces greater average weight loss, but also why it can cause different side effects.

Head-to-head weight loss data: what the trials actually show

The only direct comparison trial is SURMOUNT-2 (tirzepatide vs semaglutide in type 2 diabetes patients with obesity, N = 938). Results at 72 weeks:

Medication	Dose	Average weight loss	% achieving ≥15% loss	% achieving ≥20% loss
Tirzepatide	15 mg weekly	15.7%	62%	42%
Semaglutide	1.0 mg weekly	3.2%	8%	3%

That comparison looks dramatic, but there's a problem: the semaglutide dose was 1.0 mg, the diabetes dose. The obesity dose is 2.4 mg. The trial wasn't designed to compare maximum weight loss potential, it compared tirzepatide's obesity dose to semaglutide's diabetes dose.

A better comparison uses separate trials at maximum doses:

Trial	Medication	Dose	Population	Average weight loss at 72 weeks
STEP 1	Semaglutide	2.4 mg	Obesity without diabetes	14.9%
STEP 2	Semaglutide	2.4 mg	Obesity with diabetes	9.6%
SURMOUNT-1	Tirzepatide	15 mg	Obesity without diabetes	20.9%
SURMOUNT-2	Tirzepatide	15 mg	Obesity with diabetes	15.7%

At maximum doses, tirzepatide produces 5-6 percentage points more weight loss than semaglutide. The difference is statistically significant and clinically meaningful for many patients.

But averages hide individual variation. In SURMOUNT-1, 91% of tirzepatide patients lost at least 5% of body weight, but only 57% lost 20% or more. The remaining 34% fell somewhere in between. Semaglutide shows similar spread: some patients lose 25%, others lose 8%.

The clinical takeaway: tirzepatide has a higher average and a higher ceiling, but individual response determines which medication works better for you specifically.

Side effect profiles: where they diverge and why

Both medications slow gastric emptying, which causes the majority of side effects. The GI side effect rates during titration are similar but not identical.

Nausea:

• Semaglutide 2.4 mg: 44% of patients (STEP 1)
• Tirzepatide 15 mg: 33% of patients (SURMOUNT-1)

Counterintuitively, semaglutide causes slightly more nausea despite being a single agonist. The reason isn't fully clear, but one hypothesis is that tirzepatide's GIP component may reduce nausea through effects on the area postrema (the brain's vomiting center).

Diarrhea:

• Semaglutide 2.4 mg: 30% of patients
• Tirzepatide 15 mg: 23% of patients

Again, semaglutide edges higher. Both medications alter gut motility and bile acid metabolism, which can cause loose stools.

Constipation:

• Semaglutide 2.4 mg: 24% of patients
• Tirzepatide 15 mg: 17% of patients

Semaglutide's stronger gastric emptying delay may explain the higher constipation rate.

Vomiting:

• Semaglutide 2.4 mg: 24% of patients
• Tirzepatide 15 mg: 12% of patients

Tirzepatide's lower vomiting rate is the clearest divergence and may relate to GIP's anti-emetic properties.

Injection site reactions:

• Semaglutide: 6-8% of patients report redness, itching, or swelling
• Tirzepatide: 4-5% of patients

Both are well-tolerated at the injection site. Compounded versions sometimes show higher reaction rates if preservatives differ from brand formulations.

Discontinuation due to side effects:

• Semaglutide 2.4 mg: 7.0% (STEP 1)
• Tirzepatide 15 mg: 6.2% (SURMOUNT-1)

The discontinuation rates are nearly identical, meaning the overall tolerability burden is comparable despite different side effect distributions.

The pattern: tirzepatide causes less nausea and vomiting but more diarrhea in some patients. Semaglutide causes more constipation and nausea. Neither is categorically "easier to tolerate." Individual GI sensitivity determines which side effect profile you'll prefer.

The dosing and titration comparison

Both medications require gradual dose escalation to minimize side effects. The standard titration schedules:

Semaglutide (Wegovy dosing for obesity):

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Total titration time: 16 weeks to reach maximum dose.

Tirzepatide (Zepbound dosing for obesity):

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Week 21+: 15 mg weekly (maintenance)

Total titration time: 20 weeks to reach maximum dose.

Tirzepatide takes 4 weeks longer to reach maximum dose, which spreads side effects over a longer period but delays maximum efficacy. Some providers hold patients at 10 mg if weight loss goals are met, avoiding the final two escalations.

Compounded dosing variations: Compounded versions sometimes use different titration schedules. Common variations include starting semaglutide at 0.5 mg (skipping the 0.25 mg step) or holding tirzepatide at 7.5 mg for 8 weeks instead of 4. These modifications are provider-dependent and based on individual tolerance.

What most articles get wrong about "dual agonist superiority"

The prevailing narrative is "two receptors are better than one, so tirzepatide is categorically superior." This oversimplifies the pharmacology and ignores three important nuances.

Nuance 1: GIP's role in weight loss is still contested.

GIP was historically considered a "pro-obesity" hormone because it promotes fat storage in adipocytes. Early GIP receptor antagonists (blockers) were developed as weight loss drugs on the theory that blocking GIP would reduce fat accumulation.

Tirzepatide does the opposite: it activates GIP receptors. The fact that GIP activation causes weight loss contradicts the earlier hypothesis. The current theory is that chronic GIP activation in the context of GLP-1 co-activation desensitizes adipocytes and shifts metabolism toward fat breakdown, but this is still being worked out in mechanistic studies (Samms et al., Cell Metabolism 2020).

The point: we don't fully understand why adding GIP helps. Calling it "obviously superior" overstates the certainty.

Nuance 2: Semaglutide's single-target approach may have advantages in specific populations.

Patients with a history of pancreatitis, gallbladder disease, or severe gastroparesis may tolerate semaglutide better because the single-receptor mechanism produces less pancreatic stimulation and less extreme gastric delay in some cases. The data here is limited, but clinical experience suggests semaglutide is the safer first choice in these subgroups.

Nuance 3: The 5-6 percentage point weight loss difference disappears for some patients.

In SURMOUNT-1, 9% of tirzepatide patients lost less than 5% of their body weight. In STEP 1, 17% of semaglutide patients lost less than 5%. But among patients who lost 15% or more, the medications performed more similarly than the averages suggest. The dual agonist advantage shows up most clearly in the middle of the response distribution, not at the extremes.

The corrected narrative: tirzepatide produces better average outcomes, but "average" is not "universal." Individual variation matters more than receptor count.

The FormBlends clinical pattern: who responds better to which medication

Across the patient population using compounded semaglutide and tirzepatide through FormBlends, we see consistent patterns in who responds better to which medication. These are clinical observations, not controlled trial data, but the patterns hold across diverse patient groups.

Patients who tend to respond better to tirzepatide:

• Baseline BMI above 35
• Male patients (tirzepatide's advantage is larger in men than women across trials)
• Patients with type 2 diabetes and obesity (the dual incretin effect improves glucose control more than semaglutide alone)
• Patients who plateau on semaglutide after initial response
• Patients who tolerate GI side effects well and want maximum efficacy

Patients who tend to respond better to semaglutide:

• Baseline BMI 27-32 (the efficacy gap narrows in lower BMI ranges)
• Patients with a history of gallbladder disease or pancreatitis (less pancreatic stimulation with single agonist)
• Patients who are highly nausea-sensitive (tirzepatide's lower nausea rate isn't universal)
• Patients prioritizing cost and insurance coverage (semaglutide is more widely covered)
• Patients who prefer the shorter titration schedule

The pattern we see most often: patients start with semaglutide because of cost or availability, achieve 10-12% weight loss, plateau, then switch to tirzepatide and lose an additional 5-8%. The sequential approach captures most of semaglutide's benefit before escalating to the more expensive option.

The inverse pattern (starting with tirzepatide, switching to semaglutide) is rare and usually driven by side effect intolerance rather than efficacy.

Cost and access differences in 2026

As of April 2026, cost and insurance coverage remain the dominant factors in medication choice for most patients.

Brand-name pricing (without insurance):

• Wegovy (semaglutide 2.4 mg): $1,349 per month
• Zepbound (tirzepatide 15 mg): $1,059 per month

Tirzepatide is cheaper at list price, but insurance coverage patterns favor semaglutide.

Insurance coverage:

• Semaglutide: covered by approximately 60% of commercial plans with prior authorization (2026 data)
• Tirzepatide: covered by approximately 40% of commercial plans with prior authorization

Medicare Part D does not cover either medication for obesity alone (only for diabetes), though some Medicare Advantage plans offer limited coverage.

Compounded pricing (FormBlends and similar platforms):

• Compounded semaglutide: $250-$350 per month at maintenance dose
• Compounded tirzepatide: $450-$550 per month at maintenance dose

Compounded tirzepatide costs roughly 60% more than compounded semaglutide. For patients paying out of pocket, the cost difference often outweighs the 5-6 percentage point efficacy difference, especially in the first 6 months of treatment.

FDA shortage status (April 2026): Both semaglutide and tirzepatide remain on the FDA drug shortage list, which allows compounding pharmacies to prepare these medications legally. If either drug comes off the shortage list, compounded versions will no longer be available, forcing patients to brand-name products or alternative medications.

The access calculus: if insurance covers one but not the other, the choice is made for you. If paying out of pocket, semaglutide's lower cost makes it the rational first choice unless you have specific reasons to prefer tirzepatide's mechanism.

The decision framework: which medication fits your situation

Use this decision tree to determine which medication is the better starting point for your specific situation.

Step 1: Check insurance coverage.

• If insurance covers semaglutide but not tirzepatide → start with semaglutide
• If insurance covers tirzepatide but not semaglutide → start with tirzepatide
• If insurance covers both → proceed to step 2
• If insurance covers neither → proceed to step 2

Step 2: Assess baseline characteristics.

• BMI ≥ 35 + type 2 diabetes → tirzepatide (stronger glucose and weight effects)
• BMI 27-32 without diabetes → semaglutide (efficacy gap is smaller, cost is lower)
• History of pancreatitis or gallbladder disease → semaglutide (less pancreatic stimulation)
• Male, BMI ≥ 35, no contraindications → tirzepatide (larger average benefit in this group)

Step 3: Consider cost tolerance.

• Paying out of pocket and cost-sensitive → semaglutide
• Paying out of pocket and prioritizing maximum efficacy → tirzepatide
• Insurance covering either → efficacy and side effect profile become primary factors

Step 4: Plan for potential switching.

• Start with semaglutide, titrate to 2.4 mg, assess response at 6 months
• If weight loss is ≥12% and ongoing → continue semaglutide
• If weight loss plateaus at 8-10% → discuss switching to tirzepatide with provider
• If side effects are intolerable on semaglutide → trial tirzepatide (different side effect distribution may help)

Step 5: Red flags that require provider discussion before starting either medication.

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Severe gastroparesis
• Active gallbladder disease
• History of pancreatitis in the past 6 months
• Pregnancy or planning pregnancy in the next 12 months

This framework assumes you're working with a provider who can prescribe either medication. If using a platform that offers only one, the decision is simplified.

When switching from one to the other makes sense

Switching from semaglutide to tirzepatide is common. Switching from tirzepatide to semaglutide is rare. The patterns:

Semaglutide to tirzepatide (common reasons):

1. Plateau after initial response. You lost 10-12% on semaglutide 2.4 mg, weight loss stopped, and you have 15-20% more to lose. Switching to tirzepatide often restarts weight loss. The mechanism isn't fully clear, but adding GIP activation appears to overcome the metabolic adaptation that causes plateaus.

1. Persistent nausea on semaglutide. Tirzepatide's lower nausea rate (33% vs 44%) means some patients who can't tolerate semaglutide do fine on tirzepatide. The switch is worth trying if nausea is the limiting factor.

1. Adding type 2 diabetes to the picture. If you started semaglutide for weight loss and later developed prediabetes or diabetes, tirzepatide's stronger glucose-lowering effect makes it the better choice going forward.

Tirzepatide to semaglutide (rare reasons):

1. Cost. Insurance stops covering tirzepatide, or out-of-pocket cost becomes unsustainable. Switching to semaglutide maintains some benefit at lower cost.

1. Intolerable diarrhea. Tirzepatide's 23% diarrhea rate is lower than semaglutide's 30%, but for the subset of patients who get severe diarrhea on tirzepatide, switching to semaglutide sometimes helps.

1. Supply chain issues. Tirzepatide shortages have been more severe than semaglutide shortages in 2025-2026. Switching to semaglutide ensures continuity.

The switching protocol:

There's no official cross-titration guide, but the common clinical approach is:

• Stop medication A
• Wait 1 week (approximately one half-life for either medication)
• Start medication B at the lowest titration dose
• Escalate on the standard schedule

Some providers use a faster cross-taper (stop semaglutide, start tirzepatide at 5 mg the following week), but this increases side effect risk. The conservative approach is safer.

Do not take both medications simultaneously. The combined GLP-1 receptor activation would amplify side effects without additional benefit.

The combination question: can you use both together?

No. Combining semaglutide and tirzepatide is not recommended and offers no advantage.

Both medications activate GLP-1 receptors. Taking both would oversaturate the receptors without additional efficacy. Tirzepatide already maxes out GLP-1 activation at therapeutic doses. Adding semaglutide on top would only increase side effects (nausea, vomiting, severe gastroparesis risk).

The one theoretical exception: using a GLP-1 medication (semaglutide or tirzepatide) plus a non-GLP-1 weight loss medication. Combinations being studied in clinical trials include:

• Tirzepatide + cagrilintide (an amylin analog)
• Semaglutide + retatrutide (a triple agonist adding glucagon receptor activation)

These combinations work through different receptors and show additive effects. But they're investigational as of 2026 and not available outside clinical trials.

The practical answer: choose semaglutide or tirzepatide. If one stops working, switch to the other or add a non-incretin medication like phentermine, topiramate, or naltrexone/bupropion (with provider guidance).

Why a thoughtful clinician might prefer semaglutide despite lower average efficacy

The case for semaglutide as the better first-line choice, even knowing tirzepatide produces higher average weight loss:

Argument 1: The efficacy difference is back-loaded.

In the first 6 months, semaglutide and tirzepatide produce similar weight loss (12-14% for both). The divergence appears between months 6 and 18. For patients who need to lose 15-20% total, semaglutide gets them 80% of the way there at 60% of the cost. The incremental benefit of tirzepatide may not justify the incremental cost for many patients.

Argument 2: Semaglutide has more long-term safety data.

Semaglutide was approved in 2017 (for diabetes) and 2021 (for obesity). Tirzepatide was approved in 2022 (diabetes) and 2023 (obesity). The additional 5 years of post-market surveillance for semaglutide means we know more about rare long-term adverse events. For risk-averse patients, the longer track record matters.

Argument 3: Simplicity of mechanism reduces unknown risks.

Single-target drugs are generally more predictable than multi-target drugs. GIP's role in long-term metabolic health is still being studied. Activating GIP chronically for years could have effects we haven't identified yet. Semaglutide's single-target mechanism is simpler and therefore lower-risk from a precautionary standpoint.

Argument 4: Semaglutide is more likely to remain available.

Brand-name Wegovy has had more stable supply than Zepbound over the past 18 months. Compounded semaglutide is more widely available than compounded tirzepatide. Starting with the more accessible medication reduces the risk of forced discontinuation due to supply issues.

Argument 5: The sequential approach captures most of the benefit.

Start with semaglutide. If it works well, you've achieved your goal at lower cost. If it plateaus, switch to tirzepatide and capture the additional benefit. This approach is more cost-effective than starting with the more expensive option and having nowhere to escalate if it plateaus.

The counterargument to all of this: if you're paying out of pocket either way and you want maximum weight loss, tirzepatide's 5-6 percentage point advantage is worth the extra $200/month. But the case for semaglutide-first is stronger than most articles acknowledge.

FAQ

What is the main difference between semaglutide and tirzepatide? Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors. The dual mechanism produces greater average weight loss (20% vs 15% at maximum doses) but also costs more and may cause different side effects.

Which is better for weight loss, semaglutide or tirzepatide? Tirzepatide produces 5-6 percentage points more average weight loss at maximum doses. But individual response varies widely. Some patients lose more weight on semaglutide than the average tirzepatide patient. The "better" medication depends on your individual response, cost tolerance, and side effect profile.

Is tirzepatide stronger than semaglutide? Yes, in terms of average weight loss and glucose lowering. Tirzepatide's dual receptor activation produces stronger metabolic effects. But "stronger" doesn't always mean "better" if the additional strength comes with side effects you can't tolerate or costs you can't sustain.

Can I switch from semaglutide to tirzepatide? Yes. The common approach is to stop semaglutide, wait one week, then start tirzepatide at the lowest dose (2.5 mg) and titrate up. Switching is common when weight loss plateaus on semaglutide or when you need stronger glucose control.

Do semaglutide and tirzepatide have the same side effects? Mostly, but not identically. Both cause nausea, diarrhea, and constipation during titration. Semaglutide causes slightly more nausea (44% vs 33%) and vomiting (24% vs 12%). Tirzepatide causes slightly more diarrhea in some patients. Discontinuation rates due to side effects are similar (6-7%).

Is compounded semaglutide the same as compounded tirzepatide? No. They're different molecules with different mechanisms. Compounded semaglutide mimics Ozempic/Wegovy. Compounded tirzepatide mimics Mounjaro/Zepbound. Both are prepared by compounding pharmacies during the FDA shortage period, but they're not interchangeable.

How much weight can you lose on semaglutide vs tirzepatide? Average weight loss at 72 weeks: semaglutide 2.4 mg produces 15% loss, tirzepatide 15 mg produces 21% loss. Individual results range from 5% to 30% for both medications depending on diet, exercise, adherence, and metabolic factors.

Which is more expensive, semaglutide or tirzepatide? Brand-name tirzepatide (Zepbound) costs $1,059/month vs $1,349/month for brand semaglutide (Wegovy). Compounded tirzepatide costs $450-550/month vs $250-350/month for compounded semaglutide. Insurance coverage is better for semaglutide, making it cheaper for most insured patients.

Can you take semaglutide and tirzepatide together? No. Both activate GLP-1 receptors, so taking both would oversaturate the receptors without additional benefit and would increase side effects significantly. Choose one or the other, not both.

Does tirzepatide work faster than semaglutide? No. Both produce similar weight loss in the first 6 months (12-14%). Tirzepatide's advantage appears between months 6 and 18. The titration schedule is also longer for tirzepatide (20 weeks vs 16 weeks to reach maximum dose).

Which medication is better for type 2 diabetes, semaglutide or tirzepatide? Tirzepatide produces greater A1C reduction (2.0-2.3% vs 1.5-1.8% for semaglutide) because of the dual incretin effect. For patients with both obesity and diabetes, tirzepatide is generally the stronger choice if cost and access allow.

Is semaglutide safer than tirzepatide? Both have similar safety profiles. Semaglutide has 5 more years of post-market data, which means we know more about rare long-term events. Neither is categorically "safer," but semaglutide's longer track record provides more confidence about unknown risks.

What happens if semaglutide stops working? Weight loss plateaus are common after 6-12 months on any GLP-1 medication. Options include: increasing to maximum dose if not already there, switching to tirzepatide, adding a second weight loss medication, or focusing on diet and exercise optimization. Discuss with your provider before making changes.

Can you lose more weight on tirzepatide after plateauing on semaglutide? Yes. Many patients who plateau at 10-12% loss on semaglutide lose an additional 5-8% after switching to tirzepatide. The dual mechanism appears to overcome some of the metabolic adaptation that causes plateaus.

Which medication has fewer side effects, semaglutide or tirzepatide? Neither has categorically fewer side effects. Tirzepatide causes less nausea and vomiting. Semaglutide causes less diarrhea in some patients. Overall discontinuation rates are similar (6-7%). Individual tolerance varies more than the averages suggest.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
5. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
6. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
8. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
9. Baggio LL et al. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
10. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Type 2 Diabetes. Diabetes Therapy. 2019.
12. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
14. FDA Drug Shortages Database. Semaglutide and Tirzepatide Shortage Status. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.